Cell Line / Strain Development
Premas offers microbial, yeast and mammalian platforms to target the expression of therapeutic proteins with varied needs of post-translational modifications and complexity of the protein.
- Premas combines significant product and process development knowledge to derive the target strain and possible vector combinations. Premas has developed novel signal sequences for periplasmic and extracellular expression (secretary) for therapeutics. We have also performed a number of studies to change Inclusion body expression to periplasmic expression. This has allowed for a Gene to IND of metabolic disorder IND therapeutic protein in 9 months.
- Yeast Strain, Pichia pastoris and Saccharomyces cerevisiae – the platform technologies with vectors and strains have been used developing certain class of therapeutics in Pichia. On the other hand, targets and critical reagents have been produced using the Saccharomyces strains. Along with more than 20 different vectors for the expression of proteins, these technologies have been highly successful in the expression and supply of proteins.
- CHO/HEK platforms: Premas has its own platform technology to generate human antibody library. The CHO DG44 cell line works best with our proprietary mammalian expression vectors, which have been designed for high-level stable expression in mammalian hosts. The growth and production properties of our CHO-DG44 cell line are well defined, and the feed strategy has been optimized, allowing for faster and more efficient scale-up to bioreactors. We have observed gram level expression of antibodies per litre level using this cell line and our therapeutic candidates have reached preclinical stage showing very encouraging results.